Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Eukaryotic cells undergo continuous telomere shortening as a consequence of multiple rounds of replications. During tumorigenesis, cells have to acquire telomere DNA maintenance mechanisms (TMMs) in order to counteract telomere shortening, to preserve telomeres from DNA damage repair systems and to avoid telomere-mediated senescence and/or apoptosis. For this reason, telomere maintenance is an essential step in cancer progression. Most human tumors maintain their telomeres expressing telomerase, whereas a lower but significant proportion activates the alternative lengthening of telomeres (ALT) pathway. However, evidence about the coexistence of ALT and telomerase has been found both in vivo in the same cancer populations and in vitro in engineered cellular models, making the distinction between telomerase- and ALT-positive tumors elusive. Indeed, after the development of drugs able to target telomerase, the capability for some cancer cells to escape death, switching from telomerase to ALT, was highlighted. Unfortunately, to date, the mechanism underlying the possible switching or the coexistence of telomerase and ALT within the same cell or populations is not completely understood and different factors could be involved. In recent years, different studies have tried to shed light on the complex regulation network that controls the transition between the two TMMs, suggesting a role for embryonic cancer origin, epigenetic modifications, and specific genes activation—both in vivo and in vitro. In this review, we examine recent findings about the cancer-associated differential activation of the two known TMMs and the possible factors implicated in this process. Furthermore, some studies on cancers are also described that did not display any TMM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 2×
“In humans, telomerase activity is known to be upregulated in those cells that need to maintain an active proliferative and renewal potential, such as embryonic stem cells and germ-line cells [12].”
BackgroundTelomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 10×
“Since histone and chromatin structure disorders might provide a suitable genomic environment for ALT induction [48,108–110], it was shown that ATRX, DAXX and hTERT depletion, together with telomere induced DNA damage and dysfunction, are needed to induce switch from telomerase- to ALT-positive cell lines [102].”
BackgroundMethodInfluentialShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“Telomeres are conserved nucleoprotein structures localized at the ends of eukaryotic linear chromosomes, that in human consist of (TTAGGG)n repeats [1], which interact with six proteins that form the “shelterin complex” [2].”
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917 · cited 2×
“This process determines the loss of about 200 nucleotides for each cell cycle and when telomeres reach a threshold length, the cell escape from cell cycle activating senescence or apoptosis [3].”
BackgroundDriver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Olovnikov (1973) · doi:10.1016/0022-5193(73)90198-7 · Cited by 1,847
Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R. (1997) · Nature Medicine · doi:10.1038/nm1197-1271 · Cited by 1,292 · cited 3×
“Very recently, it was demonstrated that highly aggressive metastatic melanoma cells were not able to maintain telomeres, as was already suggested by previous studies [94,117].”
BackgroundResultTelomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279 · cited 1×
“Well-known markers of ALT include heterogeneous telomere length [14,21]; high level of telomere-sister chromatid exchanges (T-SCEs) [17]; extrachromosomal telomeric repeats DNA (ECTRs) [22,23]; and a specialized telomeric nuclear structure called ALT-associated PML (promyelocytic leukemia protein) bodies (APBs) [24].”
BackgroundAltered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083 · cited 1×
“Among TMM-positive cancers, anyway, while the majority of tested tumors (80–85%) display telomerase activity, those arising from mesenchymal tissues including bone, soft tissues, neuroendocrine systems, peripheral nervous system and central nervous system are mostly characterized by ALT activity [19,32,33] (Table 1).”
BackgroundAn alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942 · cited 1×
“Type I yeast survivors are telomerase-negative yeast cells that maintain telomere lengths by the amplification of the subtelomeric Y’ region through a recombination-dependent mechanism involving RAD51, RAD54, RAD55, RAD57 and RAD52 [87,88].”
BackgroundRecurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., de Lange, T., De, S., Petrini, J. H. J., Sung, P. A., Jasin, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002772 · Cited by 629
Systematic analysis of telomere length and somatic alterations in 31 cancer types
Barthel, F. P., Wei, W., Tang, M., Martinez-Ledesma, E., Hu, X., Amin, S. B., Akdemir, K. C., Seth, S., Song, X., Wang, Q., et al. (2017) · Nature Genetics · doi:10.1038/ng.3781 · Cited by 614 · cited 5×
“2%), kidney cromophobe carcinoma (80%) [25] (Table 1).”
BackgroundInfluentialHeaphy, C. M., Subhawong, A. P., Hong, S.-M., Goggins, M. G., Montgomery, E. A., Gabrielson, E., Netto, G. J., Epstein, J. I., Lotan, T. L., Westra, W. H., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.018 · Cited by 516
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism
Stewart, S. A., Hahn, W. C., O'Connor, B. F., Banner, E. N., Lundberg, A. S., Modha, P., Mizuno, H., Brooks, M. W., Fleming, M., Zimonjic, D. B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182407599 · Cited by 431 · cited 1×
“On the other hand, stem cells, germ line cells and the majority of tumors show telomerase activity [12,13].”
BackgroundConditional telomerase induction causes proliferation of hair follicle stem cells
Sarin, K. Y., Cheung, P., Gilison, D., Lee, E., Tennen, R. I., Wang, E., Artandi, M. K., Oro, A. E., & Artandi, S. E. (2005) · Nature · doi:10.1038/nature03836 · Cited by 425
Laud, P. R., Multani, A. S., Bailey, S. M., Wu, L., Ma, J., Kingsley, C., Lebel, M., Pathak, S., DePinho, R. A., & Chang, S. (2005) · Genes & Development · doi:10.1101/gad.1321305 · Cited by 190
Comaills, V., Kabeche, L., Morris, R., Buisson, R., Yu, M., Madden, M. W., LiCausi, J. A., Boukhali, M., Tajima, K., Pan, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.022 · Cited by 124
Development of Retinoblastoma in the Absence of Telomerase Activity
Gupta, J., Han, L.-P., Wang, P., Gallie, B. L., & Bacchetti, S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.16.1152 · Cited by 74 · cited 1×
“Indeed, in 1996 Gupta and coworkers found that samples collected from telomerase-positive retinoblastomas patients displayed also very long telomeres [93]; while in 1997 a study on characterization of different types telomerase-positive cancers, showed that some of them (melanoma and ovarian carcinoma) displayed heter…”
Background
Cited by
Silence at the End: How Drosophila Regulates Expression and Transposition of Telomeric Retroelements
Cacchione, S., Cenci, G., & Raffa, G. D. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.06.004 · Cited by 51
Cell Immortalization: In Vivo Molecular Bases and In Vitro Techniques for Obtention
de Bardet, J. C., Cardentey, C. R., González, B. L., Patrone, D., Mulet, I. L., Siniscalco, D., & Robinson-Agramonte, M. D. L. A. (2023) · BioTech · doi:10.3390/biotech12010014 · Cited by 35
Metadata
- Authors
- De Vitis, M., Berardinelli, F., & Sgura, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-02-18
- Volume
- 19
- Issue
- 2
- Pages
- 606
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2793030121
- Cited by
- 182
- References
- 20
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.